Publisher: John Wiley & Sons Inc
E-ISSN: 1931-2253|26|21|12-14
ISSN: 0959-6682
Source: PRESCRIBER, Vol.26, Iss.21, 2015-11, pp. : 12-14
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Lisdexamfetamine is now licensed for use in adults with attention deficit hyperactivity disorder (ADHD) under the brand name Elvanse Adult. This article summarises its indications and adverse effects and discusses clinical trial evidence for its efficacy in adults.
Related content
By Ginsberg Lawrence Katic Alain Adeyi Ben Dirks Bryan Babcock Thomas Lasser Robert Scheckner Brian Adler Lenard A.
Current Medical Research and Opinion, Vol. 27, Iss. 6, 2011-06 ,pp. :
Diagnosis and management of ADHD: a new way forward?
Community Practitioner, Vol. 82, Iss. 10, 2009-10 ,pp. :
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 69, Iss. 4, 2015-04 ,pp. :
Management of Buried Penis in Adults
Urologia Internationalis, Vol. 61, Iss. 3, 1999-02 ,pp. :